HR Execs on the Move

Thrive Earlier Detection

www.thrivedetect.com

 
A cancer diagnosis is something no one wants to hear. Today, it is often detected late, once it has spread and treatment options are often limited. But cancer is curable if caught in the earlier stages. At Thrive Earlier Detection, our goal is to transform this outlook: to catch cancer earlier, when it can be more effectively treated. We are developing CancerSEEK, a blood-based test that is designed to be affordable and utilized as part of routine medical care to detect multiple types of cancer at earlier stages. Our approach goes beyond a cancer diagnosis. We are developing a platform ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Frank Diehl
Executive Vice President & Head of Product Solutions Profile
Raynie Smith
Senior Director Total Rewards and Learning Profile

Similar Companies

IDbyDNA

Delivering on our promise to identify any microbe, from any sample, anywhere in the world will take a team of dedicated, passionate, and experienced individuals. The members of our team at IDbyDNA have a strong track record of building successful organizations and bring a breadth of multi-disciplinary experience including; microbial genomics, bioinformatics, software engineering, laboratory medicine, and commercialization. In concert with the global community of researchers, clinicians, industry partners and policy makers, we will revolutionize microbial detection and bring new solutions to solve problems that are not currently addressable with today`s technologies.

Oxford Instruments PLC

Oxford Instruments PLC is a Carteret, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ALX Oncology

ALX Oncology is a clinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.

LC Sciences

LC Sciences is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cydan

Cydan Development is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential.